1.A survey and analysis on disease self-management status among patients with chronic obstructive pulmonary disease
Yueqiong LIU ; Yunfen NIU ; Guili SHANG ; Zhengde LIU ; Zhengxiang GU ; Yin LI ; Xianghe LI
Chinese Journal of Primary Medicine and Pharmacy 2025;32(7):1013-1018
Objective:To investigate the disease self-management status of patients with chronic obstructive pulmonary disease (COPD) and its influential factors, providing evidence for the development of effective management strategies.Methods:A total of 483 patients with chronic obstructive pulmonary disease (COPD) who received treatment at Wenshan People's Hospital from April 2023 to April 2024 were included in this study. Their disease self-management status was assessed, and one-way analysis of variance and multiple linear regression analysis were conducted to identify the factors influencing patients' self-management abilities.Results:Among the 483 patients studied, only 2.9% (14/483) showed a complete understanding of their disease, while 21.12% (102/483) had some understanding of how to manage it. Only 34.38% (166/483) of the patients used inhalants outside the hospital as required, of which only 40.96% (68/166) used them regularly as required by doctors, and 60.84% (101/106) of the patients inhaled correctly. One-way analysis of variance and multiple linear regression analysis results showed that the factors affecting patients' self-management included COPD classification, smoking, life satisfaction, disease self-cognition, exercise habits, lung function, and gender ( t = 2.35, -2.22, -5.76, 4.37, -2.22, 5.09, -3.64, all P < 0.05). Conclusions:Patients with COPD exhibit poor disease self-management awareness and medication compliance. Patient's ability to self-manage their disease is associated with COPD classification, lung function, smoking, exercise habits, gender, life satisfaction, and disease self-cognition. Therefore, it is essential to develop appropriate intervention measures based on these factors, focusing on enhancing patients' self-management awareness and abilities to improve their quality of life.
2.A survey and analysis on disease self-management status among patients with chronic obstructive pulmonary disease
Yueqiong LIU ; Yunfen NIU ; Guili SHANG ; Zhengde LIU ; Zhengxiang GU ; Yin LI ; Xianghe LI
Chinese Journal of Primary Medicine and Pharmacy 2025;32(7):1013-1018
Objective:To investigate the disease self-management status of patients with chronic obstructive pulmonary disease (COPD) and its influential factors, providing evidence for the development of effective management strategies.Methods:A total of 483 patients with chronic obstructive pulmonary disease (COPD) who received treatment at Wenshan People's Hospital from April 2023 to April 2024 were included in this study. Their disease self-management status was assessed, and one-way analysis of variance and multiple linear regression analysis were conducted to identify the factors influencing patients' self-management abilities.Results:Among the 483 patients studied, only 2.9% (14/483) showed a complete understanding of their disease, while 21.12% (102/483) had some understanding of how to manage it. Only 34.38% (166/483) of the patients used inhalants outside the hospital as required, of which only 40.96% (68/166) used them regularly as required by doctors, and 60.84% (101/106) of the patients inhaled correctly. One-way analysis of variance and multiple linear regression analysis results showed that the factors affecting patients' self-management included COPD classification, smoking, life satisfaction, disease self-cognition, exercise habits, lung function, and gender ( t = 2.35, -2.22, -5.76, 4.37, -2.22, 5.09, -3.64, all P < 0.05). Conclusions:Patients with COPD exhibit poor disease self-management awareness and medication compliance. Patient's ability to self-manage their disease is associated with COPD classification, lung function, smoking, exercise habits, gender, life satisfaction, and disease self-cognition. Therefore, it is essential to develop appropriate intervention measures based on these factors, focusing on enhancing patients' self-management awareness and abilities to improve their quality of life.
3.Exploratory use of ddPCR in monitoring Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplantation in children
Dilmurat DILARA ; Junhong AI ; Jiao TIAN ; Mengjia LIU ; Ran WANG ; Zhengde XIE
Chinese Journal of Experimental and Clinical Virology 2024;38(3):331-336
Objective:This study aimed to introduce droplet digital PCR (ddPCR) for monitoring Epstein-Barr virus (EBV) infection after allogeneic hematopoietic stem cell transplantation (alloHSCT) in children and assess its viability as a complementary detection method in clinical settings.Methods:A total of 290 blood samples from 47 children undergoing alloHSCT were collected. Both ddPCR and real-time quantitative PCR (qPCR) were employed to detect EBV DNA load in plasma, with a comparison of detection efficiencies between the two methods. Continuous monitoring of 39 children was conducted to observe dynamic changes in EBV DNA load in plasma and analyze the merits and drawbacks of both methods.Results:The EBV positive detection rate of ddPCR was significantly higher than that of qPCR ( χ2=20.25, P<0.001), particularly in samples with low viral loads. Among the children monitored continuously for EBV DNA, 14 out of 39 exhibited positive ddPCR result. Notably, in two cases where patients displayed rash and fever symptoms with positive ddPCR result but negative qPCR result, ddPCR demonstrated heightened sensitivity in early EBV infection detection. Conclusions:ddPCR holds certain advantages in monitoring EBV infection post-alloHSCT in children, especially for samples with low viral loads. However, as this method is still in the exploratory stage of clinical application, further research and practice are needed to validate its utility.
4.Analysis of the epidemic characteristics and disease burden of hospitalized children with viral myocarditis in China from 2016 to 2021
Luci HUANG ; Wei SHAO ; Lingyun GUO ; Yiliang FU ; Fei LI ; Hui XU ; Guoshuang FENG ; Lu GAO ; Zhengde XIE ; Yue YUAN ; Gang LIU ; Xiangpeng CHEN
Chinese Journal of Experimental and Clinical Virology 2024;38(4):432-438
Objective:This study aimed to provide basic data for the prevention, diagnosis and treatment of pediatric viral myocarditis (VMC) in China through analyzing the epidemic characteristics and disease burden of pediatric inpatients with VMC from 2016 to 2021.Methods:We performed a descriptive statistical analysis to the age, genders, seasons, regions and hospitalization cost and days of pediatric VMC inpatients and the death. All of the information was obtained from 27 Children′s hospitals or Maternal and Child Health hospitals of 23 provinces of China from 2016 to 2021.Results:A total of 7 647 599 cases including 1 646 VMC inpatients were admitted into our study. The annual numbers of hospitalizations were 173, 227, 313, 301, 295 and 337, with the hospitalized constituent ratios being 14.9/100 000, 17.9/100 000, 23.0/100 000, 20.5/100 000, 26.5/100 000 and 26.4/100 000 from 2016 to 2021. In recent 6 years, the proportion of VMC hospitalizations had increased yearly ( P<0.001), and had associated with the onset age ( P<0.001). Aged 12-≤18 years owned the highest hospitalized constituent ratio. The Northeast of China owned the largest number of VMC inpatients, and the East second to it. Among the 1 646 VMC children, there were 68 deaths, with the hospitalized case fatality rate of 4.13%. There were no significant differences between genders, age, seasons, years and fatality rate of VMC inpatients. For the diseases burden, the median of hospitalization days of all VMC inpatients was 10 days (IQR 6, 21), and the median of hospitalization cost was 1 1 842.3 RMB (IQR 6 969.22, 19 714.78). The median of hospitalization days of deceased VMC children was only 1 day (IQR 1, 3), the median cost could be 8 874.03 RMB (IQR 5 277.94, 5 6 151.59). Conclusions:In this study, we found that proportion of hospitalization of VMC children increased year by year, adolescence might be a risk factor of VMC. The fatality of VMC inpatients could be up to 4.13%, and the death led to a huge economic burden of society, family and individuals.
5.Landscape of respiratory syncytial virus.
Yuping DUAN ; Zimeng LIU ; Na ZANG ; Bingbing CONG ; Yuqing SHI ; Lili XU ; Mingyue JIANG ; Peixin WANG ; Jing ZOU ; Han ZHANG ; Ziheng FENG ; Luzhao FENG ; Lili REN ; Enmei LIU ; You LI ; Yan ZHANG ; Zhengde XIE
Chinese Medical Journal 2024;137(24):2953-2978
Respiratory syncytial virus (RSV) is an enveloped, negative-sense, single-stranded RNA virus of the Orthopneumovirus genus of the Pneumoviridae family in the order Mononegavirales. RSV can cause acute upper and lower respiratory tract infections, sometimes with extrapulmonary complications. The disease burden of RSV infection is enormous, mainly affecting infants and older adults aged 75 years or above. Currently, treatment options for RSV are largely supportive. Prevention strategies remain a critical focus, with efforts centered on vaccine development and the use of prophylactic monoclonal antibodies. To date, three RSV vaccines have been approved for active immunization among individuals aged 60 years and above. For children who are not eligible for these vaccines, passive immunization is recommended. A newly approved prophylactic monoclonal antibody, Nirsevimab, which offers enhanced neutralizing activity and an extended half-life, provides exceptional protection for high-risk infants and young children. This review provides a comprehensive and detailed exploration of RSV's virology, immunology, pathogenesis, epidemiology, clinical manifestations, treatment options, and prevention strategies.
Humans
;
Respiratory Syncytial Virus Infections/prevention & control*
;
Respiratory Syncytial Viruses/pathogenicity*
;
Respiratory Syncytial Virus, Human/pathogenicity*
;
Antiviral Agents/therapeutic use*
6.Diagnosis, treatment and prevention of severe acute respiratory syndrome coronavirus 2 infection in children: experts′ consensus statement (Fifth Edition)updated for the Omicron variant
Rongmeng JIANG ; Zhengde XIE ; Yi JIANG ; Xiaoxia LU ; Runming JIN ; Yuejie ZHENG ; Yunxiao SHANG ; Baoping XU ; Zhisheng LIU ; Gen LU ; Jikui DENG ; Guanghua LIU ; Xiaochuan WANG ; Jianshe WANG ; Luzhao FENG ; Wei LIU ; Yi ZHENG ; Sainan SHU ; Min LU ; Wanjun LUO ; Miao LIU ; Yuxia CUI ; Leping YE ; Adong SHEN ; Gang LIU ; Liwei GAO ; Lijuan XIONG ; Yan BAI ; Likai LIN ; Zhuang WEI ; Fengxia XUE ; Tianyou WANG ; Dongchi ZHAO ; Zhengyan ZHAO ; Jianbo SHAO ; Wong Wing-kin GARY ; Yanxia HE ; Xingwang LI ; Yonghong YANG ; Kunling SHEN
Chinese Journal of Applied Clinical Pediatrics 2023;38(1):20-30
China has classified the Corona Virus Disease 2019(COVID-19) as a statutory category B infectious disease and managed it according to Category B since January 8, 2023.In view that Omicron variant is currently the main epidemic strain in China, in order to guide the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection in children with the times, refer to the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10 th Edition), Expert Consensus on Diagnosis, Treatment and Prevention of Novel Coronavirus Infection in Children (Fourth Edition) and the Diagnosis and Treatment Strategy for Pediatric Related Viral Infections.The Expert Consensus on the Diagnosis, Treatment and Prevention of Novel Coronavirus Infection in Children (Fifth Edition) has been formulated and updated accordingly on related etiology, epidemiology, pathogenic mechanism, clinical manifestations, auxiliary examination, diagnosis and treatment, and added key points for the treatment of COVID-19 related encephalopathy, fulminating myocarditis and other serious complications for clinical reference.
7.A multicenter study on human parainfluenza virus infections among children with community-acquired pneumonia from 2014 to 2020
Shiqi CAI ; Baoping XU ; Changchong LI ; Yun SUN ; Gen LU ; Rong JIN ; Yunxiao SHANG ; Yunlian ZHOU ; Ling CAO ; Aihuan CHEN ; Li DENG ; Yixiao BAO ; Limin NING ; Zhou FU ; Fang GU ; Shuilian YU ; Chunyan LIU ; Ju YIN ; Kunling SHEN ; Yun ZHU ; Zhengde XIE
Chinese Journal of Experimental and Clinical Virology 2023;37(5):472-479
Objective:To investigate the epidemiological and clinical characteristics of human parainfluenza viruses (HPIVs) infection among hospitalized children with community-acquired pneumonia (CAP) in China, and provide basic data for diagnosis, treatment and prevention of HPIVs infection.Methods:From November 2014 to February 2020, 5 448 hospitalized children with CAP were enrolled in 14 hospitals in 11 provinces and municipalities directly under the Central Government in southern China and northern China. Nasopharyngeal aspirates or throat swabs were collected, and the nucleic acids of 18 types respiratory viruses including HPIV1-4 were screened by suspension array technology. Demographic data and clinical information were collected for statistical analysis.Results:The total detection rate of HPIVs in 5 448 children with CAP was 8.83% (481/5 448), and the detection rate in males was higher than that in females (62.79% vs. 37.21%; χ2=0.000, P=0.992). The detection rate of HPIVs in 1~< 3 years age group was higher than that in other age groups, and the difference was statistically significant ( χ2=61.893, P<0.001). The detection rate of HPIVs in the northern region was higher than that in the southern region (9.02% vs 8.65%), but the difference was not statistically significant ( χ2=0.239, P=0.625). The prevalence of HPIV1-4 in northern and southern China was not completely same. HPIV1 was mainly prevalent in autumn in both northern and southern regions. HPIV2 was prevalent in summer in northern China, and the detection rate was low in southern China. HPIV3 reached its peak in both spring and summer in both northern and southern China, but its duration was longer in southern China than in northern China. HPIV4 is mainly popular in autumn in both southern China and northern China. Among 481 children infected with HPIVs, 58.42% (281/481) were infected with HPIV alone, and the main clinical manifestations were cough (90.75%) and fever (68.68%). Out of the HPIV-positive cases, 42.62% (205/481) were co-infected with another type of HPIV or a different virus, while 11.43% (55/481) had co-infections with two or more different viruses. HPIV3 was the most common type of co-infection with other viruses. HPIV3 infection accounted for the largest proportion (76.80%) in 47 HPIVs-positive children with severe pneumonia. Conclusions:HPIVs is one of the most important pathogens causing CAP in children in China, and children under 3 years of age are the main populations of HPIVs infection. The prevalence characteristics of all types of HPIVs in children in the north and south are not completely same. HPIV3 is the dominant type of HPIV infections and causes more severe diseases.
8.Viral nucleic acid tests and application
Ran WANG ; Linlin ZHANG ; Jiao TIAN ; Mengjia LIU ; Zhengde XIE
Chinese Journal of Experimental and Clinical Virology 2022;36(3):337-345
Viral infectious diseases are a class of major diseases that seriously affect human life and health, and the causes of emerging infectious diseases are mostly viral pathogens. Rapid and accurate viral pathogen tests are of great significance for the clinical diagnosis and control of such infectious diseases. As an indispensable auxiliary diagnostic method, viral nucleic acid tests have the advantages of high sensitivity and specificity, etc., and have become an important method to identify the cause, determine the treatment schedule, and evaluate the treatment effect and prognosis. A series of method based on polymerase chain reaction, isothermal amplification technology or genome sequencing, respectively, have been successfully applied to viral nucleic acid detection. In this review, we will discuss the tests and applications of viral nucleic acid detection commonly used in clinical practice, as well as the issues that need attention in the interpretation of the result, to help the accurate diagnosis and treatment of viral infectious diseases.
9.Expert consensus on the diagnosis, treatment and prevention of monkeypox in children
Rongmeng JIANG ; Yuejie ZHENG ; Lei ZHOU ; Luzhao FENG ; Lin MA ; Baoping XU ; Hongmei XU ; Wei LIU ; Zhengde XIE ; Jikui DENG ; Lijuan XIONG ; Wanjun LUO ; Zhisheng LIU ; Sainan SHU ; Jianshe WANG ; Yi JIANG ; Yunxiao SHANG ; Miao LIU ; Liwei GAO ; Zhuang WEI ; Guanghua LIU ; Gang LIU ; Wei XIANG ; Yuxia CUI ; Gen LU ; Min LU ; Xiaoxia LU ; Runming JIN ; Yan BAI ; Leping YE ; Dongchi ZHAO ; Adong SHEN ; Xiang MA ; Qinghua LU ; Fengxia XUE ; Jianbo SHAO ; Tianyou WANG ; Zhengyan ZHAO ; Xingwang LI ; Yonghong YANG ; Kunling SHEN
Chinese Journal of Applied Clinical Pediatrics 2022;37(13):964-973
Monkeypox is a zoonotic disease.Previous studies have shown that children are vulnerable to monkeypox and are also at high risk for severe disease or complications.In order to improve pediatricians′ understanding of monkeypox and achieve early detection, early diagnosis, early treatment and early disposal, the committee composed of more than 40 experts in the related fields of infectious diseases, pediatrics, infection control and public health formulate this expert consensus, on the basis of the latest clinical management and infection prevention and control for monkeypox released by the World Health Organization (WHO), the guidelines for diagnosis and treatment of monkeypox (version 2022) issued by National Health Commission of the People′s Republic of China and other relevant documents.During the development of this consensus, multidisciplinary experts have repeatedly demonstrated the etiology, epidemiology, transmission, clinical manifestations, laboratory examinations, diagnosis and differential diagnosis, treatment, discharge criteria, prevention, case management process and key points of prevention and control about monkeypox.
10.Diagnosis, treatment and prevention of severe acute respiratory syndrome coronavirus 2 infection in children: experts′ consensus statement (Fourth Edition)
Rongmeng JIANG ; Zhengde XIE ; Yi JIANG ; Xiaoxia LU ; Runming JIN ; Yuejie ZHENG ; Yunxiao SHANG ; Baoping XU ; Zhisheng LIU ; Gen LU ; Jikui DENG ; Guanghua LIU ; Xiaochuan WANG ; Jianshe WANG ; Luzhao FENG ; Wei LIU ; Yi ZHENG ; Sainan SHU ; Min LU ; Wanjun LUO ; Miao LIU ; Yuxia CUI ; Leping YE ; Adong SHEN ; Gang LIU ; Liwei GAO ; Lijuan XIONG ; Yan BAI ; Likai LIN ; Zhuang WEI ; Fengxia XUE ; Tianyou WANG ; Dongchi ZHAO ; Zhengyan ZHAO ; Jianbo SHAO ; Kwok-keung Daniel NG ; Wing-kin Gary WONG ; Xingwang LI ; Yonghong YANG ; Kunling SHEN
Chinese Journal of Applied Clinical Pediatrics 2022;37(14):1053-1065
Since December 2019, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infections have raged globally for more than 2 years.China has always adopted scientific and effective prevention and control measures to achieved some success.However, with the continuous variation of SARS-CoV-2 cases and imported cases from abroad, the prevention and control work has become more difficult and complex.With the variation of the mutant strain, the number of cases in children changed, and some new special symptoms and complications were found, which proposed a new topic for the prevention and treatment of SARS-CoV-2 infection in children in China.Based on the third edition, the present consensus according to the characteristics of the new strain, expounded the etiology, pathology, pathogenesis, and according to the clinical characteristics and experience of children′s cases, and puts forward recommendations on the diagnostic criteria, laboratory examination, treatment, prevention and control of children′s cases for providing reference for further guidance of effective prevention and treatment of SARS-CoV-2 infection in children in China.

Result Analysis
Print
Save
E-mail